Teva and Allergan Reach Proposed Settlements Totaling $6.6 Billion over Opioid Allegations

  • A group of 8 AGs reached agreements with Teva Pharmaceutical Industries Ltd. and Allergan Limited, as well as their respective affiliated entities, to resolve allegations regarding the companies’ roles in contributing to the nationwide opioid crisis.
  • The Teva and Allergan settlements, the latest in a series of settlements between AGs and manufacturers, distributors, and retailers of opioids, resolve allegations that the companies illegally marketed opioid medications that they manufactured and failed to maintain effective diversion controls.
  • Under the terms of the settlements, Teva is required to pay $4.24 billion and Allergan is required to pay $2.37 billion, inclusive of amounts the companies have paid to previously settling states. Teva will provide up to $1.2 billion in generic naloxone—an opioid antagonist that rapidly reverses the effects of an overdose. Allergan and Teva are prohibited from promoting opioid products or engaging in opioid-related lobbying, among other things. Allergan, which does not currently manufacture any opioid products, is prohibited from manufacturing or selling them in the future.
  • Another 35 states, as well as the District of Columbia and several U.S. territories, will have thirty days from the date of the agreements to decide whether or not to join in the proposed settlement.